Results 261 to 270 of about 1,010,901 (298)
Some of the next articles are maybe not open access.
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
New England Journal of Medicine, 2023Patients with prostate cancer who have high-risk biochemical recurrence have an increased risk of progression. The efficacy and safety of enzalutamide plus androgen-deprivation therapy and enzalutamide monotherapy, as compared with androgen-deprivation therapy alone, are unknown.In this phase 3 trial, we enrolled patients with prostate cancer who had ...
Stephen J. Freedland +19 more
openaire +3 more sources
Evaluation of biochemical variables in patients with recurrent aphthous stomatitis
Journal of Stomatology, Oral and Maxillofacial Surgery, 2023We investigated the effects of various biochemical agents on the etiopathogenesis of recurrent aphthous stomatitis (RAS).We enrolled 70 RAS patients and 70 healthy volunteers. Peripheral venous blood samples were collected. We performed complete blood counts, then measured the levels of ferritin, vitamin B12, iron, magnesium, phosphorus, calcium ...
Mehtap Koparal +4 more
openaire +2 more sources
Current Opinion in Urology, 2005
Through the prostate-specific antigen era, the proportion of men less than 55 years old with newly diagnosed prostate cancer more than doubled to almost 15%. As increasing numbers of men are living longer with prostate cancer, larger proportions will eventually present to our collective practices with rising prostate-specific antigen levels.
John F, Ward, Judd W, Moul
openaire +2 more sources
Through the prostate-specific antigen era, the proportion of men less than 55 years old with newly diagnosed prostate cancer more than doubled to almost 15%. As increasing numbers of men are living longer with prostate cancer, larger proportions will eventually present to our collective practices with rising prostate-specific antigen levels.
John F, Ward, Judd W, Moul
openaire +2 more sources
Current Opinion in Urology, 2005
The introduction of prostate-specific antigen into clinical practice heralded a dramatic shift in the epidemiology of prostate cancer. The diagnosis and treatment of lower stage disease in younger men with fewer competing co-morbidities has resulted in a longer period of post-treatment cancer surveillance and the potential for disease recurrence.
John F, Ward, Judd W, Moul
openaire +2 more sources
The introduction of prostate-specific antigen into clinical practice heralded a dramatic shift in the epidemiology of prostate cancer. The diagnosis and treatment of lower stage disease in younger men with fewer competing co-morbidities has resulted in a longer period of post-treatment cancer surveillance and the potential for disease recurrence.
John F, Ward, Judd W, Moul
openaire +2 more sources
The Prostate, 2018
BackgroundRates of metastatic progression (MP) and prostate cancer mortality (PCSM) are variable after biochemical recurrence (BCR) in patients who underwent radical prostatectomy (RP). To describe long‐term oncological outcomes of BCR patients and to analyze risk factors for further outcomes in these men with a special focus on RP‐BCR time.MethodsWe ...
Raisa S. Pompe +9 more
openaire +2 more sources
BackgroundRates of metastatic progression (MP) and prostate cancer mortality (PCSM) are variable after biochemical recurrence (BCR) in patients who underwent radical prostatectomy (RP). To describe long‐term oncological outcomes of BCR patients and to analyze risk factors for further outcomes in these men with a special focus on RP‐BCR time.MethodsWe ...
Raisa S. Pompe +9 more
openaire +2 more sources
Biochemical Recurrence: A Valuable Endpoint?
2013Clinically relevant outcomes such as distant metastases and death from prostate cancer do not occur for many years after definitive treatment for localized prostate cancer. In view of the long natural history of prostate cancer, the identification and validation of surrogate endpoints that can be measured earlier and correlate with clinical progression
openaire +1 more source
MAGI2 is an independent predictor of biochemical recurrence in prostate cancer
The Prostate, 2018BackgroundMembrane‐associated guanylate kinase, WW and PDZ domain‐containing protein 2 (MAGI2) promotes the activity of phosphatase and tensin homolog (PTEN). Recent studies suggest that dysregulation of this signaling pathway has a role in prostate carcinogenesis.
Stephanie N. David +7 more
openaire +2 more sources
Salvage radiotherapy for biochemical recurrence after radical prostatectomy
BJU International, 2005OBJECTIVE To evaluate the clinical outcome of salvage radiotherapy (RT) for biochemical recurrence after radical prostatectomy (RP) at our institution. PATIENTS AND METHODS Between March 1999 and January 2004, 37 patients had salvage ...
Akito, Terai +4 more
openaire +2 more sources
Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer
Clinical Genitourinary Cancer, 2015Circulating tumor cells (CTCs) have known prognostic implications in metastatic castration-resistant prostate cancer, but little is known regarding its utility in biochemical recurrence (BR) of prostate cancer. The primary objectives were to determine whether CTCs are measurable in patients with BR and whether it can reliably predict prostate-specific ...
Jeanny B. Aragon-Ching +9 more
openaire +2 more sources
Biochemical and Histological Analysis of 'Recurrent' Macular Corneal Dystrophy
Archives of Ophthalmology, 1982A patient with macular corneal dystrophy who had a successful 6-mm corneal transplant 23 years ago underwent a second keratoplasty for marked irregular astigmatism. The excised button, which contained the original graft and a rim of host cornea, was divided into several portions.
D A, Newsome +4 more
openaire +2 more sources